Andrew Levin is a Partner and Managing Director at RA Capital Management, where he focuses on building and investing in early-stage life sciences companies. An MD from Harvard and a PhD from MIT, he leverages his deep scientific and medical background to spearhead drug discovery and development efforts.
Andrew is a vocal supporter of free speech within the biotech community and shows a strong interest in the complexities of healthcare policy. His public posts reveal a critical perspective on industry practices, particularly concerning the role of Pharmacy Benefit Managers (PBMs) in the healthcare system.
He co-founded several biotech companies, including Carnot Pharm and Climb Bio (formerly Eliem Therapeutics), where he also served as CEO.
Andrew Levin
President, Founder at Carnot Pharma
Boston, Massachusetts, United States
Overview
Topics They Care About
Life Sciences Investing
As a Partner at RA Capital, his primary role is investing in and building early-stage private companies across biotech and healthcare.
Biotech Entrepreneurship
Co-founded multiple companies, including Carnot Pharm and Climb Bio, and has served as CEO, demonstrating a commitment to building new ventures.
Healthcare Policy
He publicly shares strong opinions on healthcare system villains like Pharmacy Benefit Managers (PBMs), indicating an interest in industry reform.
Media Appearances
Andrew has no verified media appearances
Work History
2016
President, Founder at Carnot Pharma
2015
Partner and Managing Director at RA Capital Management, LLC
2012 - 2015
Vice President at H.I.G. Capital
2010 - 2012
Director at Clinton Health Access Initiative
Education
2005 - 2007
MD from Harvard Medical School
2000 - 2005
PhD from Massachusetts Institute of Technology
More Information
Social Presence :
Prographics :
Exp : 16
Location : Boston, Massachusetts, United States
Job Level : Leadership
Designation : President, Founder at Carnot Pharma
